UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
(Sharecast News) - London stocks closed with little direction on Friday as investors weighed fresh economic data, including signs of slowing private sector growth. The FTSE 100 index edged down 0.04% ...
The S&P Global Flash UK PMI revealed the steepest fall in private sector employment since November 2020. The wage pressures ...
GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...
Sterling rose to USD1.2665 on Friday morning from USD1.2638 at the time of the London equities close on Thursday. The euro climbed to USD1.0481 from USD1.0470. Against the yen, the dollar rose to ...
LONDON: The main UK stock indexes fell for a third straight session on Thursday, trading near two-week lows, as heavyweight ...
The UK's major stock indexes have declined for the third consecutive session, influenced by mixed corporate earnings and ...
Shares of GSK PLC GSK rose 1.79% to £14.47 Thursday, on what proved to be an all-around rough trading session for the stock ...
For decades, UK governments have promised major housebuilding initiatives, setting targets of 300,000 homes per year or, most ...
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback